Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
jig.jp, First Half Ordinary Profit Decreases by 3%, Jul-Sep Ordinary Profit Decreases by 11%
5244 jig.jp co.,ltd. 【J-GAAP】
Earnings Reportjig.jp co.,ltd. <5244> [TSE Growth] announced its financial results after the market closed on November 13th (15:30). The consolidated ordinary profit for the cumulative second quarter of the fiscal year ending March 2026 (April to September) decreased 3.1% from the same period last year to 0.98 billion yen. However, Progress toward the full-year plan of 1.91 billion yen was 51.5%, almost the same as the four-year average of 49.2%.
Based on the first-half performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated ordinary profit for the October to March period (second half) is expected to grow 10.6% from the same period last year, reaching 0.92 billion yen.
In the most recent three-month period, from July to September (2Q), the consolidated ordinary profit decreased to 0.43 billion yen, a 10.6% decrease compared to the same period last year. The operating profit margin decreased from 16.8% in the same period last year to 13.7%.
Kabutan News
Actual Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Progress Rate vs. First Half | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Apr - Sep, 2023 | 6,013 | 881 | 900 | 594 | 14.1 | 49.4 | Nov 14, 2023 | J-GAAP |
| Apr - Sep, 2024 | 6,672 | 1,094 | 1,019 | 509 | 12.1 | 54.8 | Nov 14, 2024 | J-GAAP |
| Apr - Sep, 2025 | 7,359 | 1,075 | 987 | 630 | 15.1 | 51.5 | Nov 13, 2025 | J-GAAP |
| YoY | +10.3% | -1.7% | -3.1% | +23.8% | +24.8% |
First Half Results vs. Previous Guidance
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Apr - Sep, 2025 Guidance | ー | ー | ー | ー | - | 0 | May 14, 2025 | J-GAAP |
| Apr - Sep, 2025 Results | 7,359 | 1,075 | 987 | 630 | 15.1 | 0 | Nov 13, 2025 | J-GAAP |
| Revision Rate | - | - | - | - | - |
Current Period Guidance
Second Half Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Oct - Mar, 2024 | 7,124 | 918 | 839 | 568 | 13.6 | 2.59 | May 14, 2025 | J-GAAP |
| Oct - Mar, 2025 Guidance | 7,841 | 1,040 | 928 | 590 | 14.3 | 2.93 | Nov 13, 2025 | J-GAAP |
| YoY | +10.1% | +13.3% | +10.6% | +3.9% | +5.5% |
Current Period Guidance
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Mar, 2024 | 12,247 | 1,804 | 1,823 | 1,214 | 28.9 | 5.78 | May 14, 2024 | J-GAAP |
| Mar, 2025 | 13,796 | 2,012 | 1,858 | 1,077 | 25.7 | 2.59 | May 14, 2025 | J-GAAP |
| Mar, 2026 Guidance | 15,200 | 2,115 | 1,915 | 1,220 | 29.5 | 2.93 | May 14, 2025 | J-GAAP |
| YoY | +10.2% | +5.1% | +3.1% | +13.3% | +15.0% |
Quarterly Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Operating Profit Margin | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Jul - Sep, 2024 | 3,373 | 566 | 491 | 220 | 5.2 | 16.8 | Nov 14, 2024 | J-GAAP |
| Oct - Dec, 2024 | 3,572 | 444 | 403 | 280 | 6.7 | 12.4 | Feb 14, 2025 | J-GAAP |
| Jan - Mar, 2025 | 3,552 | 474 | 436 | 288 | 6.9 | 13.3 | May 14, 2025 | J-GAAP |
| Apr - Jun, 2025 | 3,699 | 573 | 548 | 341 | 8.2 | 15.5 | Aug 13, 2025 | J-GAAP |
| Jul - Sep, 2025 | 3,660 | 502 | 439 | 289 | 6.9 | 13.7 | Nov 13, 2025 | J-GAAP |
| YoY | +8.5% | -11.3% | -10.6% | +31.4% | +32.3% |
Related Articles
Noile-Immune Biotech, The Current Fiscal Year's Undisclosed Net Income to Narrow
SPRIX, 13% Increase in Ordinary Profit for The Current Fiscal Year
ITFOR, First Half Ordinary Profit Revised Downward to an Unexpected 21%Decrease, Current Fiscal Year Dividend Revised Upward by 20 Yen
Jibannet, First Half Net Income Turns to Loss, Jul-Sep Net Income Decreases by 40%
FRUTA FRUTA, First Half Ordinary Profit Increases by 3.7 times, Jul-Sep Ordinary Profit Increases by 40%
JAPAN INSULATION, First Half Ordinary Profit Increases by 73%, Jul-Sep Ordinary Profit Increases by 65%
BRUNO, Jul-Sep (1Q) Ordinary Profit Turns to Profit
CHANGE Holdings, First Half Net Income Decreases by 25%
Rebase, Ordinary Profit Forecast for the Fiscal Year Revised Downward by 86%
AlphaPolis, Ordinary Profit Forecast for the Fiscal Year Revised Upward by 1%